cultures from a 50-year-old Chinese woman, who had myelodysplastic syndrome and was hospitalized for pneumonia. She had been previously treated with chemotherapy and had multiple admissions for infection. The same phenotypic and karyotypic methods as the first patient were used to identify the isolate. The API 20C AUX profile was 2152134 at 48 hours (98.5% certainty for C. dubliniensis). The MIC of fluconazole by E-test was also 0.75 µg/mL. Pancytopenia developed, and the patient’s condition deteriorated. She died of pneumonia despite transfusions and treatment with broad-spectrum antibiotics and amphotericin B. Microbiologic investigations for bacteria, tuberculosis, and Legionella, and viruses did not yield positive results except for Corynebacterium species in the bronchial alveolar lavage fluid.

Although C. dubliniensis was first associated with oral candidiasis in HIV-infected persons (3), several reports now link the organism to non-HIV patients who were immunosuppressed due to chemotherapy, hemato logic malignancy (4), and end-stage liver disease (1). Our two patients were not HIV positive but were immunosuppressed. In vitro susceptibility results showed that our patients should have responded to the usual antifungal treatment. However, they died despite appropriate therapy.

Acknowledgment
We acknowledge David Ellis for help in confirming the isolates.

Ai Ling Tan, Grace CY Wang, and Yoon Wan Chiu
Singapore General Hospital, Singapore

References

O157:H7 Shiga Toxin-Producing Escherichia coli Strains Associated with Sporadic Cases of Diarrhea in São Paulo, Brazil

To the Editor: Shiga toxin-producing Escherichia coli (STEC) strains are associated with a spectrum of diseases ranging from mild to severe bloody diarrhea and complications such as hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (1). Since STEC was linked with hemorrhagic colitis in 1982 (2), strains—particularly serotype O157:H7—have been associated with numerous outbreaks and many sporadic cases of infections worldwide. STEC is now a major cause of foodborne disease, primarily in the United States, Canada, Japan, and Europe (1,3). Although most sporadic cases and outbreaks have been reported from developed countries, human infections associated with STEC strains have also been described in Latin American countries, including Argentina and Chile (3). In Brazil, STEC infections have been related to sporadic cases of nonbloody diarrhea caused by non-O157 strains (4,5); serotype O157:H7 has not been previously isolated from human infections in our country.

We report the characterization of three O157:H7 strains isolated in São Paulo State, Brazil. The first strain was identified among a laboratory collection of 2,573 E. coli strains that were retrospectively analyzed and isolated from patients with diarrhea in São Paulo State, from 1976 through 1999, at the Central Laboratory of Instituto Adolfo Lutz (IAL). This strain was isolated in 1990 from an 18-year-old patient with diarrheal disease who had AIDS. The two other O157 strains were recently isolated from a 4-year-old girl with bloody diarrhea and from an adult with severe diarrhea. Both patients were admitted to the same hospital at Campinas, São Paulo State, in June and July 2001, respectively. The strains, isolated by routine diagnostic procedures on MacConkey agar plates, were presumptively identified as E. coli O157 by standard methods with specific O157 antiserum. These last two strains were confirmed as sorbitol-negative E. coli O157 at the IAL Regional Laboratory at Campinas and were sent to the IAL Central Laboratory for further characterization.

Guidelines for Letters. Letters discussing a recent Emerging Infectious Diseases article (400-500 words, 5-10 references) should be received within 4 weeks of the article’s publication. Letters reporting preliminary data (500-1,000 words, 10 references) should not duplicate other material published or submitted for publication, should not be divided into sections, and should avoid figures or tables. All letters have the same authorship, financial disclosure, and acknowledgment requirements as full articles and should include a word count. For more guidance on manuscript preparation, see Emerging Infectious Diseases Instructions to Authors. Send letters to the Editor, Emerging Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd., MS D 61, Atlanta, GA 30333, USA, or e-mail: eideditor@cdc.gov.

Letters Editor: Patricia M. Quinlisk, Des Moines, Iowa, USA
The three O157 E. coli strains underwent biochemical identification and serotyping by standard methods. Enterohemolysin production was determined according to Beutin et al. (5). Polymerase chain reaction assays were used to detect the stx1 and stx2 genes (6), and colony hybridization assays with specific DNA probes for stx1, stx2, and eae genes were performed as described (7). Cytotoxicity to Vero cells was assayed as described (4). The strains were characterized as sorbitol-negative O157:H7, containing the stx2 and eae sequences. The enterohemolytic phenotype and production of Stx were also observed in all isolates.

To our knowledge, these O157:H7 STEC strains are the first to be associated with human diseases in Brazil. Cultivation of stool specimens in sorbitol MacConkey agar is strongly recommended for screening O157 strains, and, indeed, all three strains were isolated from MacConkey agar plates. Laboratories should attempt to examine stool specimens from all patients (children and adults) with HUS, severe diarrhea (nonbloody and bloody stools) requiring hospitalization, or both, as well as from patients reporting a history of bloody diarrhea.

Despite the importance of O157:H7 serotype in causing life-threatening complications such as HUS and the isolation of this serotype from clinical specimens in São Paulo State, the relatively low prevalence of this serotype in healthy dairy and beef cattle in Brazil (8), as well as the occurrence of other non-O157 STEC strains associated with human infections (4,5,9), suggest that E. coli O157:H7 may not be as frequent as non-O157 STEC strains in our country.

References

Updates in Wilderness and Extreme Medicine
Adam's Mark Hotel
Denver, Colorado
November 9-10, 2002
The course will provide updated approaches to prevention and treatment of health issues relating to wilderness travel. Speakers are internationally recognized authorities on wilderness medicine. The course will immediately precede, and occur in the same venue as, the ASTMH 51st annual meeting. Category I CME credit available for approximately 9 hours.
For additional information, contact ASTMH by telephone: 847-480-9592; e-mail: astmh@astmh.org; or web site: http://www.astmh.org

ASTMH 51st Annual Meeting
Adam's Mark Hotel
Denver, Colorado
November 10-14, 2002
Highlights include sessions on DNA vaccines, molecular parasitology, pathogenesis of malaria, cytokines and parasite antigens, epidemiology of tropical diseases and mucosal immunity. The society has issued a call for papers with a deadline of June 1, 2002, for online abstract submissions at http://abstract.cor-netser.com/. Category I CME credit available for 30 hours.
For additional information, contact ASTMH by telephone: 847-480-9592; e-mail: astmh@astmh.org; or web site: http://www.astmh.org

- Instituto Adolfo Lutz, São Paulo, Brazil; †Laboratório de Análises Clínicas Dr João Antônio Vozza, Campinas, São Paulo, Brazil; ‡Instituto Adolfo Lutz, Campinas, São Paulo, Brazil; and §Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, Brazil